Kenvue Inc.

KVUE

NYSE; chemicals; SIC 2844, Perfumes, Cosmetics & Other Toilet Preparations; CIK 0001944048

None

No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $27.1B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	thin data not computable: distress
Inputs computable	6 of 14
Graded from	filings received through Feb 20, 2026 254 days before the rescan; latest periodic filing 10-Q received Oct 30, 2026
Last close	$19.34 2026-10-30; market equity $37.2B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 20, 2026

At Kenvue, our purpose is to realize the extraordinary power of everyday care. As a global leader at the intersection of healthcare and consumer goods, we are the world's largest pure-play consumer health company by revenue with $15.1 billion in Net sales in the fiscal year 2025. By combining the power of science with meaningful consumer insights and our digital strategy, we empower consumers to live healthier lives every day.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 39.4						
Gross profitability	32.5%	21.4%		17.0	359	2025-12-28
Return on invested capital	not computable	9.3%				
a prior annual debt, equity, and cash observation is required						
Accruals ratio	(2.8%)	(4.2%)		61.7	398	2025-12-28

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	not computable	2.2 pts				
five annual gross margins are required; found 3						
Solvency, sleeve percentile 80.3						
Twelve-month failure probability	not computable	0.04%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	1.21	3.41		67.6	300	2025-12-28
Net debt to EBITDA	not computable	1.88x				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-28						
Interest coverage	not computable	4.16x				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-28						
Current ratio	0.96x	2.20x		93.1	421	2025-12-28
Growth and financing, sleeve percentile 65.0						
Revenue growth, three-year compound	not computable	1.2%				
four annual observations are required; found 3						
Free cash flow growth, three-year compound	not computable	12.5%				
four consecutive annual FCF observations are required; found 3						
Reinvestment rate	(6.5%)	21.8%		69.8	170	2025-12-28
Asset growth, three years	not computable	2.9%				
four annual observations are required; found 3						
Net share issuance, one year	0.3%	0.0%		60.1	317	2026-02-13

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	6 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	28.8%	11.0%	68
Distance from 52-week high	(2.9%)	(24.7%)	94
EBIT to enterprise value	5.5%	3.8%	68
Free cash flow yield	4.6%	3.4%	65
Book value to price	0.27	0.38	36
Sales to price	0.41	0.55	38
Composite equity issuance, five years	not computable	(10.0%)	
Relative strength against the sector, log excess return	0.11	0.00	64

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-28	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Cash, filings, liquidity	
Cash and equivalents	$1.0B
Operating cash flow, four quarters	$2.7B
Months of runway	not finite
Days since last periodic filing	2 (10-Q received Oct 30, 2026)
Median daily dollar volume, 63 sessions	$382.4M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$8.8B	2025-12-28	2026-02-20	10-K	26-000030
2	assets	us-gaap:Assets	$27.1B	2025-12-28	2026-02-20	10-K	26-000030
3	operating income	us-gaap:OperatingIncomeLoss	$2.5B	2023-12-31	2026-02-20	10-K	26-000030
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$2.2B	2023-12-31	2026-02-20	10-K	26-000030
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$526.0M	2023-12-31	2026-02-20	10-K	26-000030
6	total debt	us-gaap:LongTermDebt	$7.7B	2023-12-31	2024-03-01	10-K	24-000057
7	book equity	us-gaap:StockholdersEquity	$11.2B	2023-12-31	2026-02-20	10-K	26-000030
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.4B	2023-12-31	2025-02-24	10-K	25-000033
9	net income	us-gaap:NetIncomeLoss	$1.5B	2025-12-28	2026-02-20	10-K	26-000030
10	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$2.2B	2025-12-28	2026-02-20	10-K	26-000030
11	assets	us-gaap:Assets	$25.6B	2024-12-29	2026-02-20	10-K	26-000030
12	current assets	us-gaap:AssetsCurrent	$5.7B	2025-12-28	2026-02-20	10-K	26-000030
13	current liabilities	us-gaap:LiabilitiesCurrent	$5.9B	2025-12-28	2026-02-20	10-K	26-000030
14	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$204.0M	2025-12-28	2026-02-20	10-K	26-000030
15	operating income	us-gaap:OperatingIncomeLoss	$2.4B	2025-12-28	2026-02-20	10-K	26-000030
16	book equity	us-gaap:StockholdersEquity	$10.8B	2025-12-28	2026-02-20	10-K	26-000030
17	liabilities	us-gaap:Liabilities	$16.3B	2025-12-28	2026-02-20	10-K	26-000030
18	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$627.0M	2023-12-31	2026-02-20	10-K	26-000030
19	interest expense	us-gaap:InterestExpense	$250.0M	2023-12-31	2024-03-01	10-K	24-000057
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$15.1B	2025-12-28	2026-02-20	10-K	26-000030
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$15.5B	2024-12-29	2026-02-20	10-K	26-000030
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$15.4B	2023-12-31	2026-02-20	10-K	26-000030
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$475.0M	2025-12-28	2026-02-20	10-K	26-000030
24	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$557.0M	2025-12-28	2026-02-20	10-K	26-000030
25	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$2.0B	2025-12-28	2026-02-20	10-K	26-000030
26	income tax	us-gaap:IncomeTaxExpenseBenefit	$529.0M	2025-12-28	2026-02-20	10-K	26-000030
27	current assets	us-gaap:AssetsCurrent	$5.5B	2024-12-29	2026-02-20	10-K	26-000030
28	current liabilities	us-gaap:LiabilitiesCurrent	$5.7B	2024-12-29	2026-02-20	10-K	26-000030
29	assets	us-gaap:Assets	$27.9B	2023-12-31	2025-02-24	10-K	25-000033
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,916,732,090	2026-02-13	2026-02-20	10-K	26-000030
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,911,240,720	2025-02-14	2025-02-24	10-K	25-000033

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.